Media

Treatments in Development for Muscle-invasive Bladder Cancer - Min Yuen Teo

Details
Alicia Morgans, MD, MPH and Min Yuen Teo, MD, discuss areas of unmet need in bladder cancer treatment, including in the management of patients with non-metastatic muscle-invasive bladder cancer, as well as those who develop metastatic or progressive disease. At Memorial Sloan Kettering, Dr. Teo’s research group has focused on three themes: How to improve the efficacy of cisplatin-based chemotherap...

A Prostate Cancer Patient Journey, a Spouse's View - Becky McLain

Details
(Length of Interview: 4 min) As a partner of someone with prostate cancer, Becky McLain shares a glimpse of what it is like for her as a spouse of someone with prostate cancer and for her entire family after diagnosis. Biography: Becky McLain, spouse of a prostate cancer patient Read the Full Video Transcript

Becky McLain: My name is Becky McLain and I am here because my husband has prostate cancer. As a partner of someone going through prostate cancer, it's a different process, different perspective. No person is an island, and so even though they have that diagnosis, in a way you do as well because you walk alongside them. Or, your whole family is really involved. So, I think it's important to find support for yourself as well. Often as the mom or the partner, you're supporting your spouse but you're also trying to take care of children and helping them process emotion. So, it is important for you to find a group of people that you can just be raw and honest with, and not have to try to protect them. I think that's something important.

Each person is unique. What is going to bring energy to one might not to another, so I think you need to figure out yourself where you're going to get that strength and support. For me, my faith is huge. I couldn't do it without my faith. I have an incredible group of friends. We meet weekly. They have been a great source of strength. Try to walk, try to eat healthy. Those things, try to do that as well. I think the other thing is to celebrate. There is good in the midst of this, and to take those opportunities to celebrate. Little things are big things. I know when Mark was going through radiation, we had celebration Friday. He would have it five days, Friday was the last day that week, and we would do something fun. So, just to try to build those into life because life does continue.

Again, find that support. Make sure you're taking care of yourself. Also, I think communication. What that person is going to need from you is going to vary from day to day. It may not just be one thing. It might be multi-level. From one day it's, "I need you to listen to me," another day it's, "I want to forget about this. Let's just pretend it's not happening." So, being sensitive to that and communicating, I think that's important.

For me, I am an organized person so that felt natural to be the note-taker, and help put together a list of questions, also to consolidate the story because if you're going for a second opinion or you're switching doctors, you need to have that story. So, taking on that role. But again, I think you need to play to each others' strengths and figure out that piece. I also think it is, and I've said this too, just to have that second set of eyes and ears, and to be able to process that together later. My advice for someone going with someone would be, organize some questions. Organize your information. Take as many notes as you can, and you're writing fast and when you're in that moment, it feels overwhelming because there's so much, but then being able to process it together.

I would say, have hope. Have hope. It's a challenge, it's a journey, but there is also joy in the midst of it. So, never give up that hope.

Women Pursuing a Career in Medicine: Highlights on the Prostate Cancer Foundation Scientific Retreat - Alicia Morgans

Details
Kamari Collins, Laila Williams, and Valerie Martinez from San Diego High School join Alicia Morgans at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) to share their visions for their own futures based upon their experiences as a part of the science, Technology, Engineering, and Math (STEM) program at MedTech Academy in San Diego, California. These three dedicated young wo...

The BCG Shortage - What To Do In This Setting - Joshua Meeks

Details
Alicia Morgans and Joshua Meeks discuss the current shortage of Bacille Calmette-Guérin (BCG) and how it is impacting clinicians' treatment decisions and ongoing clinical trials. Dr. Meeks shares his thoughts behind the shortage and provides his strategy for clinicians and teams to make the proper patient selection to use the available BCG effectively to cover as many patients as possible. Biograp...

Advancements in BCG Unresponsive Bladder Cancer: Highlights from the 2019 SUO Meeting - Joshua Meeks

Details
Alicia Morgans and Joshua Meeks discuss the recent advancements in treating Bacille Calmette-Guérin (BCG) unresponsive bladder cancer that came from the 2019 meeting of the Society of Urologic Oncology. They review the many promising clinical trials including some early data from the Phase III VICINIUM trial as well as a promising combination intravesical chemotherapy options for non-muscle-invasi...

An Update on the PRONOUNCE Trial, Comparing the Occurrence of Major Adverse Cardiovascular Events in Patients with Prostate Cancer and Cardiovascular Disease - Susan Slovin

Details
Susan Slovin joins Alicia Morgans to provide an update on the PRONOUNCE trial, the first Phase III prospective trial comparing a GnRH antagonist with a GnRH agonist with the endpoints of major adverse cardiovascular events. It explores how cardiovascular disease is not only affecting our patient's wellbeing on androgen deprivation therapy but also gives us for the first time a lot of different end...

A New Era In Systemic Therapies, Pembrolizumab for High Risk Non-Muscle Invasive BCG-Refractory Patients - Arjun Balar

Details
Arjun Balar and Alicia Morgans discuss the new era in systemic therapies in non-muscle invasive bladder cancer (NMIBC) focusing on the systemic checkpoint inhibitor, pembrolizumab that resulted in the US FDA approval of pembrolizumab for treatment in early bladder cancer. Historically being in the domain of urologic oncologists, Drs. Morgans and Balar discuss the importance of the medical oncologi...

Systemic Therapies in High Volume & Low Volume Disease in the Treatment of Metastatic Hormone Sensitive Prostate Cancer from the STAMPEDE Trial- Nick James

Details
Nick James, a Professor of Clinical Oncology at the Institute of Cancer Research joins Alicia Morgans at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) and discusses the developments around the high-volume/low-volume disease in metastatic hormone-sensitive disease from the STAMPEDE trial. They also discuss relapsed disease versus de novo metastatic disease. Biographies: P...

Data from the RTOG 9601 Study: Treating Prostate Cancer Patients with Low-Volume Disease - Daniel Spratt

Details
At the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019), Daniel Spratt joins Charles Ryan to discuss an update of the Shipley data (NEJM 2017) from the RTOG 9601 study. The question discussed is how should we be treating patients who have favorable, lower-volume disease? They also assess the antiandrogen therapy, bicalutamide, that was used in this study versus those available...

Study of Baseline PSA Screening of Men (45 years old) - Peter Albers

Details
Peter Albers discusses his study of baseline PSA screening of young men across the nation of Germany. The study consists of 45-year-old men who are randomized in two cohorts, one group gets a PSA immediately and the other cohort has a delay of five years. The initial PSA value determines the patient’s risk-adapted strategy and dictates the schedule of further testing. Dr. Albers states that the tr...